MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$4.71
+0.10 (+2.17%)
Open$4.70
Previous Close$4.61
Day High$4.82
Day Low$4.68
52W High$15.47
52W Low$3.76
Volume—
Avg Volume1.02M
Market Cap405.48M
P/E Ratio—
EPS$-4.34
SectorBiotechnology
Analyst Ratings
Sell
18 analysts
Price Target
+779.8% upside
Current
$4.71
$4.71
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 875.86M | 821.32M | 74.53M |
| Net Income | -133,116,705 | -112,345,306 | -15,758,896 |
| Profit Margin | -15.2% | -14.4% | -21.1% |
| EBITDA | -63,995,683 | -57,010,407 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.6% | +6.6% | +5.3% |
| Debt/Equity | 0.06 | 0.06 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |